Business Wire

Leonard A. Lauder Decides Not to Stand for Re-Election to The Estée Lauder Companies Board of Directors

24.8.2023 23:25:00 EEST | Business Wire | Press release

Share

The Estée Lauder Companies announced today that Chairman Emeritus Leonard A. Lauder has informed the Company of his decision not to stand for re-election to the Company’s Board of Directors (the “Board”) at the annual meeting in November. Leonard Lauder remains Chairman Emeritus of the Company. Pursuant to the stockholders’ agreement among Lauder family members and the Company, Leonard Lauder has the right to designate two directors of the Company. In addition to his son William P. Lauder, who serves as Executive Chairman, Leonard Lauder has designated his son Gary M. Lauder to serve on the Board. The Board has nominated Gary Lauder and will include his name among the nominees for election at the Company’s annual meeting in November. Gary Lauder is the Managing Director of Lauder Partners LLC, a Silicon Valley-based venture capital firm. He has been a venture capitalist since 1985, investing in over 150 private companies. Gary serves on the Board of Governors of Alzheimer’s Drug Discovery Foundation and holds a BA in International Relations from the University of Pennsylvania; a BS in Economics from the Wharton School; and an MBA from the Stanford Graduate School of Business. Gary has periodically attended the Company’s Board meetings over the years as an invited observer, which has provided him with a long-term view of the Company.

Leonard Lauder formally joined The Estée Lauder Companies in 1958 and served as President from 1972 to 1995 and as Chief Executive Officer from 1982 to 1999. He became Chairman of the Board in 1995 and served in that role through June 2009, until he was appointed Chairman Emeritus for the Company. As Chairman Emeritus, Leonard Lauder provides his advice and counsel on a variety of business topics including brand building, marketing, and understanding the global luxury consumer. He continues to play an active role as “Chief Teaching Officer,” educating leaders throughout the Company with his brand symposiums and through speaking engagements with global employees.

“My father envisioned and helped drive the growth and expansion of our Company from an iconic single brand to the global, brand-building powerhouse it is today. We’ve never wavered from his vision of being a home for the best brands and best people, all of whom are united in delivering high-quality, prestige beauty products and high-touch service and experiences, while maintaining our unique, values-driven culture,” said William P. Lauder, Executive Chairman. “It has been an incredible honor and privilege to have worked with and learned from my father over the years. I look forward to continuing to learn from him and know his passion for this industry, this Company, our employees and our consumers is as strong as ever.”

“It has been an honor and privilege to serve on the Board of the Company my mother and father created over 75 years ago,” said Leonard Lauder. “This Board is one of the best in the business. I feel confident that the Company’s leadership and Board will continue to guide our strategy to deliver long-term growth. Additionally, I continue to believe in the success of our Company through the skillful and thoughtful management by William, Fabrizio, and the entire leadership team. The nomination of Gary to the Board further reflects my family’s long-term stewardship, and our support of the vision, values, and people who will drive the Company’s future success. As Chairman Emeritus of the Company, I’m looking forward to continuing my work as advisor and “Chief Teaching Officer,” serving what I believe to be the best Company in the world.”

“On behalf of the Board, I share my deep admiration and appreciation to Leonard for his invaluable contributions to the Company as an officer and as a member of the Board. He is a visionary whose creative thinking is unmatched in the industry. His innovative insights will continue to serve as inspiration for us all,” said Charlene Barshefsky, the Company’s Presiding Director.

In addition to his activities with The Estée Lauder Companies, Leonard Lauder is extremely involved in the worlds of education, art, politics, and philanthropy. He is a Charter Trustee of the University of Pennsylvania and a founding member of the Board of Governors of its Joseph H. Lauder Institute of Management and International Studies. Leonard Lauder became a Trustee of the Whitney Museum of American Art in New York City in 1977 and currently serves as its Chairman Emeritus. He is Co-Founder and Co-Chairman of the Alzheimer’s Drug Discovery Foundation; Honorary Chairman of the Breast Cancer Research Foundation; a member of the Council on Foreign Relations; a Trustee of the Aspen Institute; and a member of the President’s Council of Memorial Sloan-Kettering Hospital. Leonard Lauder also served on the Advisory Committee for Trade Negotiations under President Ronald Reagan. Among his honors, he has been named an Officier de la Légion d’Honneur by France and recognized by the U.S. Navy Supply Corps Foundation with its Distinguished Alumni Award, was the 2013 recipient of the Palazzo Strozzi Renaissance Man of the Year Award, and was named a 2014 Living Landmark by the New York Landmarks Conservancy.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

ELC-C

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors: Rainey Mancini
rmancini@estee.com

Media: Jill Marvin
jimarvin@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye